Europe’s Cross-Border Medtech Deal Activity Rises in Q4 2020

There was a flurry of cross-border medical device deal activity in the last three months of 2020.

Statistics from GlobalData show the medtech industry experienced a 15.9 percent rise in cross-border deal activity during the fourth quarter, ended Dec. 31, 2020. The activity was led by Exact Sciences’ $410 million acquisition of Base Genomics.
 
A total of 51 cross border deals worth $1.49 billion were announced for the region during the fourth quarter of 2020 compared with Q4 2019’s final quarter average of 44 deals.
 
Of all the deal types, M&A recorded most activity in Q4 2020 with 25, representing a 49.02 percent share for the region.
 
In second place was venture financing with 19 deals, followed by private equity deals with seven transactions, respectively capturing a 37.2 percent and 13.7 percent share of the overall cross border deal activity for the quarter.
 
In terms of value of cross border deals, M&A was the leading category in the United Kingdom’s medical devices industry with $818.5 million, while private equity and venture financing deals totalled $415.46 million and $253.34 million, respectively.
 
The top five medical devices cross border deals accounted for a 76.5 percent share of the overall value during Q4 2020.
 
The combined value of the top five cross border deals stood at $1.14 billion compared with the overall value of $1.49 billion recorded for the quarter.
 
The top five medical devices industry cross border deals of Q4 2020 tracked by GlobalData were:

• Exact Sciences’ $410 millio acquisition of Base Genomics
• The $286.77 million private equity deal with Bioneb by GEM Global YieldSCS
• Richter Gedeon Nyrt’s $263.5 million asset transaction with Janssen Pharmaceuticals
• The $110 million venture financing deal with Sophia Genetics by ACE &SA, Alychlo, aMoon Partners, Credit Suisse Group, Endeavour Vision, Eurazeo Growth, Famille C Invest, Generation Investment Management, Hitachi Ventures, Pictet & Cie Group and Swisscom Ventures
• Gyrus Capital’s private equity with LivaNova for $72.47 million.